MaxQ AI Partners with EnvoyAI to Distribute Accipio Artificial Intelligence Solutions to U.S. and E.U. Acute Care
Physicians Will Have Full Access to MaxQ’s Accipio Intracranial Hemorrhage Detection Platform for the First Time, by Leveraging the TeraRecon Northstar AI Results Explorer
MaxQ AI, a clinical diagnostics intelligence platform company, announced a distribution agreement with the EnvoyAI subsidiary of TeraRecon. TeraRecon is a leader in advanced visualization and artificial intelligence solutions. As part of this agreement, MaxQ’s innovative Accipio™ intracranial hemorrhage (ICH) platform, components of which have received FDA Breakthrough status and whose Accipio Ix™ ICH identification and triaging solution recently received FDA clearance, will now be a premier clinical solution available through the EnvoyAI Exchange marketplace. Accipio Ix will be sold through EnvoyAI and TeraRecon’s comprehensive PACS distribution channels and to the TeraRecon installed base of customers. The Accipio platform, working in combination with TeraRecon’s Northstar AI Results Explorer™, offers powerful first-of-kind physician workflows for ICH that are unmatched in radiology today.
“Our agreement with EnvoyAI will enable hospitals around the world to have access to our revolutionary AI-enabled Accipio platform for approved commercial use in their emergency rooms and for clinical research purposes,” said Chris Schnee, SVP Commercial Operations for MaxQ AI. “This partnership further accelerates the adoption of MaxQ solutions by acute care hospitals, which are TeraRecon’s core customer base. We are proud to be collaborating commercially with a market share leader in radiology advanced visualization. With Accipio Ix™ having both FDA clearance and CE Mark certification, U.S. and E.U. patients are soon to receive the benefit of augmented intelligence; the combination of the MaxQ AI empowerment coupled with the skills of the caregiver. Better together.”
“We believe strongly in this concept of augmented intelligence, whereby the physician remains in control, interpretations are better informed and workflow is accelerated simultaneously,” said Jeff Sorenson, President and CEO of TeraRecon. “Our Northstar AI Results Explorer™ plays a pivotal role in allowing physicians to consume Accipio Ix results in many different ways, while always respecting the physician’s preferences and belief system. This is especially useful for inclusion of the innovative, but investigational-use only results, from Accipio Ax™ and Accipio Dx™. Physicians control what results are viewed and when, where they appear in the PACS workflow, and what images and findings persist in the PACS archive. MaxQ has done an outstanding job of utilizing the EnvoyAI platform and TeraRecon’s Northstar* technology to the fullest.”
MaxQ’s Accipio platform is designed to be highly sensitive to the presence of ICH – commonly known as a brain bleed – identifying and prioritizing patients with ICH for the treating physician. Accipio Ix is the first part of the ecosystem and has received both FDA clearance and CE Mark certification. It provides a capability for rapid escalation and prioritization of a brain bleed due to stroke or head trauma and can be natively integrated into CT and PACS systems using the imaging industry-standard DICOM, installed both on-premise and in the future, cloud-capable.